Search
Filter Results
Displaying 51–60 of 804 for “retinitis clinical trial”
-
Oct 20, 2020
RP Treatment Derived from Induced Pluripotent Stem Cells Advances into Clinical Trial
The stem cells were derived from mature blood cells and coaxed to become photoreceptors
-
Jun 25, 2021
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
May 16, 2017
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
ProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
Nov 15, 2019
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Phase 1/2a human study will evaluate neural progenitors for preserving vision
-
Dec 7, 2018
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Editas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
May 2, 2022
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
The company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
Dec 2, 2022
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
Apr 12, 2021
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Development of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Jul 12, 2023
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
The emerging RNA therapy is designed to boost expression of the PRPF31 protein